Quanterix Corporation (QTRX) shares ended the last trading session 13.6% higher at $24.02. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock’s 8.4% loss over the past four weeks.
The recent launch of biomarker blood test for diagnosis of Alzheimer’s disease primarily drove Quanterix’s share prices.
This company is expected to post quarterly loss of $0.36 per share in its upcoming report, which represents a year-over-year change of +46.3%. Revenues are expected to be $26.45 million, up 12.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Quanterix Corporation, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on QTRX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Quanterix Corporation belongs to the Zacks Medical – Products industry. Another stock from the same industry, TG Therapeutics (TGTX), closed the last trading session 8.3% higher at $24.96. Over the past month, TGTX has returned -20.5%.
TG Therapeutics’ consensus EPS estimate for the upcoming report has changed +16% over the past month to -$0.25. Compared to the company’s year-ago EPS, this represents a change of +16.7%. TG Therapeutics currently boasts a Zacks Rank of #2 (Buy).
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Quanterix Corporation (QTRX) : Free Stock Analysis Report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.